chlorocresol brands
5 registered brands containing chlorocresol in Kenya.
chlorocresol
PubChem CID 1732Molecular formula: C7H7ClO
...In skeletal muscle sarcoplasmic reticulum, 4-chloro-m-cresol was found to be a potent activator of Ca2+ release mediated by a ruthenium red/caffeine-sensitive Ca2+ release channel. In cerebellar microsomes, this compound released Ca2+ from an inositol-1,4,5-trisphosphate-insensitive store, suggesting that there too it was acting at the ryanodine receptor level. When tested on PC12 cells, chlorocresol released Ca2+ from a caffeine- and thapsigargin-sensitive intracellular store. In addition, the compound was capable of releasing Ca2+ after pretreatment of PC12 cells with bradykinin, suggesting that it acts on a channel contained within an intracellular Ca2+ store that is distinct from that sensitive to inositol-1,4,5-trisphosphate. Structure-activity relationship analyses suggest that the chloro and methyl groups in chlorocresols are important for the activation of the ryanodine receptor Ca2+ release channel. The ryanodine receptor type 1 (RyR1) and type 2 (RyR2), but not type 3 (RyR3), are efficiently activated by 4-chloro-m-cresol (4-CmC). /It was/ previously /shown/ that a 173-amino acid segment of RyR1 (residues 4007-4180) is required for channel activation by 4-CmC ... present study... used site-directed mutagenesis to identify individual amino acid(s) within this region that mediate 4-CmC activation. In RyR1, substitution of 11 amino acids conserved between RyR1 and RyR2, but divergent in RyR3, with their RyR3 counterparts reduced 4-CmC sensitivity to the same degree as substitution of the entire 173-amino acid segment. Further analysis of various RyR1 mutants containing successively smaller numbers of these mutations identified 2 amino acid residues (Gln(4020) and Lys(4021)) that, when mutated to their RyR3 counterparts (Leu(3873) and Gln(3874)), abolished 4-CmC activation of RyR1. Mutation of either of these residues alone did not abolish 4-CmC sensitivity, although Q4020L partially reduced 4-CmC-induced Ca /ion/ transients. In addition, mutation of the corresponding residues in RyR3 to their RyR1 counterparts (L3873Q/Q3874K) imparted 4-CmC sensitivity to RyR3. Recordings of single RyR1 channels indicated that 4-CmC applied to either the luminal or cytoplasmic side activated the channel with equal potency. Secondary structure modeling in the vicinity of the Gln(4020)-Lys(4021) dipeptide suggests that the region contains a surface-exposed region adjacent to a hydrophobic segment, indicating that both hydrophilic and hydrophobic regions of RyR1 are necessary for 4-CmC binding to the channel and/or to translate allosteric 4-CmC binding into channel activation.
Source: PubChem (NCBI) ยท compound 1732
| Product | Manufacturer | Status | Country |
|---|---|---|---|
| BURNOX CREAM CONTAINS SILVER SULFADIAZINE USP 1.0%W/W, CHLORHEXIDINE GLUCONATE SOLUTION BP EQUIVALENT TO CHLORHEXIDNE GLUCONATE 0.2%W/W AND CHLOROCRESOL BP 0.025%W/W |
Beta Healthcare | Registered | Kenya |
| DERMA PLUS CREAM BETAMETHASONE DIPROPIONATE BP 0.064%W/W, NEOMYCIN SULPHATE BP 0.5%W/W AND CHLOROCRESOL BP 0.1%W/W |
Beta Healthcare | Registered | Kenya |
| DERMACIN CREAM CLOBETASOL PROPIONATE BP 0.05%W/W, GETAMICIN SULPHATE BP 0.1%W/W, MICONAZOLE NITRATE BP 2.0% AND CHLOROCRESOL BP 1.0%W/W |
Beta Healthcare | Registered | Kenya |
| FLUZOLE (FLUCONAZOLE GEL 0.5%) FLUCONAZOLE BP 0.5 % W/W AND CHLOROCRESOL 0.1 % WW |
Dolopharma | Registered | Kenya |
| G -DERM CREAM EACH GRAM CONTAINS: BETAMETHASONE DIPROPIONATE USP 0.643 MG, GENTAMICIN SULPHATE BP EQUIVALENT TO GENTAMICIN BASE 1 MG TOLNAFTATE USP 10 MG IODOCHLORHYDROXYQUINOLINE |
Theralife Pharma | Registered | Kenya |